Krieckaert CLM - Search Results

1

Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.

l'Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ. l'Ami MJ, et al. Among authors: krieckaert clm. Clin Exp Rheumatol. 2017 May-Jun;35(3):431-437. Epub 2017 Jan 5. Clin Exp Rheumatol. 2017. PMID: 28079512

2

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Bartelds GM, et al. JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406. JAMA. 2011. PMID: 21486979

3

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.

Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ. Jamnitski A, et al. Ann Rheum Dis. 2012 Jan;71(1):88-91. doi: 10.1136/annrheumdis-2011-200184. Epub 2011 Sep 12. Ann Rheum Dis. 2012. PMID: 21914626 Clinical Trial.

4

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner.

Krieckaert CL, Nurmohamed MT, Wolbink GJ. Krieckaert CL, et al. Ann Rheum Dis. 2012 Nov;71(11):1914-5. doi: 10.1136/annrheumdis-2012-201544. Epub 2012 May 14. Ann Rheum Dis. 2012. PMID: 22586169 No abstract available.

5

IgG4 production against adalimumab during long term treatment of RA patients.

van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ. van Schouwenburg PA, et al. J Clin Immunol. 2012 Oct;32(5):1000-6. doi: 10.1007/s10875-012-9705-0. Epub 2012 May 24. J Clin Immunol. 2012. PMID: 22622790

6

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.

Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Krieckaert CL, et al. Arthritis Rheum. 2012 Dec;64(12):3850-5. doi: 10.1002/art.34680. Arthritis Rheum. 2012. PMID: 22933315

7

Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.

Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF. Krieckaert CL, et al. Rheumatology (Oxford). 2013 Mar;52(3):547-53. doi: 10.1093/rheumatology/kes320. Epub 2012 Dec 5. Rheumatology (Oxford). 2013. PMID: 23221326

8

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.

van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. van Schouwenburg PA, et al. Ann Rheum Dis. 2013 Oct;72(10):1680-6. doi: 10.1136/annrheumdis-2012-202407. Epub 2013 Jan 7. Ann Rheum Dis. 2013. PMID: 23300118

9

Key findings towards optimising adalimumab treatment: the concentration-effect curve.

Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, Wolbink G. Pouw MF, et al. Ann Rheum Dis. 2015 Mar;74(3):513-8. doi: 10.1136/annrheumdis-2013-204172. Epub 2013 Dec 10. Ann Rheum Dis. 2015. PMID: 24326008

10

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.

Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE, van der Kleij D, Rispens T, Wolbink G, Krieckaert CL. Kneepkens EL, et al. Ann Rheum Dis. 2015 Feb;74(2):396-401. doi: 10.1136/annrheumdis-2013-204185. Epub 2013 Dec 10. Ann Rheum Dis. 2015. PMID: 24326011

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results